CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Two year safety and tolerability of tenofovir disoproxil fumarate (TDF) treatment in HBeAg negative and HBEAG positive patients with chronic hepatitis B (CHB)
DOI 10.1055/s-0029-1241403
Bibliografische Angaben
Nachweis in CareLit
Autor:innenP Buggisch, M Manns, S Mauss, T Berg, G Teuber, J Petersen, M Schuchmann, S Zeuzem, P Marcellin, J Heathcote, J Sorbel, F Rousseau
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe09/2009
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Tenofovir disoproxil fumarate (TDF) has a well established long term safety profile in HIV-1 infected patients with more than 2 million patient years of exposure. TDF has activity against hepatitis B virus (HBV) and was approved in 2008 for the treatment of CHB. Goal: To evaluate the safety and tolerability of 2 years of TDF treatment in patients with CHB. Methods: In the Phase 3 studies 102 and 103, H…
Zitieren
Zitierempfehlung
P Buggisch, M Manns, S Mauss, T Berg, G Teuber, J Petersen, M Schuchmann, S Zeuzem, P Marcellin, J Heathcote, J Sorbel, F Rousseau (2009) Two year safety and tolerability of tenofovir disoproxil fumarate (TDF) treatment in HBeAg negative and HBEAG positive patients with chronic hepatitis B (CHB). Zeitschrift für Gastroenterologie (09). https://doi.org/10.1055/s-0029-1241403
Mit CareLit weiterarbeiten